Evotec (NASDAQ:EVO) Cut to “Hold” at Berenberg Bank

Berenberg Bank cut shares of Evotec (NASDAQ:EVO) from a buy rating to a hold rating in a research report released on Thursday morning, MarketBeat Ratings reports.

Several other brokerages also recently weighed in on EVO. TD Cowen downgraded Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a report on Wednesday. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Finally, HC Wainwright decreased their price objective on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.00.

Evotec Stock Down 0.5%

Shares of EVO stock opened at $1.96 on Thursday. Evotec has a 1-year low of $1.95 and a 1-year high of $4.42. The stock’s fifty day moving average price is $2.75 and its 200 day moving average price is $3.01. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68.

Hedge Funds Weigh In On Evotec

Several hedge funds have recently made changes to their positions in the company. ABC Arbitrage SA lifted its position in Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after acquiring an additional 422,230 shares during the period. Marshall Wace LLP purchased a new stake in Evotec during the 4th quarter valued at about $40,000. HRT Financial LP purchased a new stake in Evotec during the 4th quarter valued at about $72,000. Goldman Sachs Group Inc. acquired a new position in shares of Evotec in the fourth quarter valued at about $110,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the period. 5.81% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Evotec AG and kept its $4.00 price target, signaling some confidence in longer-term upside.
• Neutral Sentiment: Analysts still expect Evotec to remain loss-making in the near term, with forecast EPS revisions showing only a gradual path toward profitability. Evotec AG stock page
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to ($0.04) from ($0.01), implying weaker-than-expected near-term earnings momentum.
• Negative Sentiment: The firm also lowered its Q4 2026 EPS forecast to ($0.02), reduced FY2026 EPS to ($0.31), and trimmed FY2027 EPS to $0.07, reinforcing concerns about slower earnings recovery.
• Negative Sentiment: Separately, Berenberg Bank downgraded Evotec from Buy to Hold, which likely added to the stock’s weakness by signaling less conviction in the near-term setup.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.